(Reuters) – The U.S. Food and Drug Administration on Friday approved Aquestive Therapeutics’ treatment for neurological disorder amyotrophic lateral sclerosis (ALS).

Aquestive has developed riluzole oral film (ROF), and will market the film under the brand name Exservan. (bit.ly/2pIFzi5)

Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel



READ SOURCE

READ  Best hay fever remedies - from nasal spray and tablets to eye drops and natural treatments

LEAVE A REPLY

Please enter your comment!
Please enter your name here